Premium
TB vaccines: current status and future perspectives
Author(s) -
Aagaard Claus,
Dietrich Jes,
Doherty Mark,
Andersen Peter
Publication year - 2009
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1038/icb.2009.14
Subject(s) - proteome , mycobacterium tuberculosis , immune system , tuberculosis , clinical trial , immunology , antigen , computational biology , fusion protein , biology , medicine , bioinformatics , genetics , pathology , gene , recombinant dna
Vaccines against intracellular pathogens such as Mycobacterium tuberculosis need to induce strong cellular immune responses. Antigen discovery programs have exploited this and used proteome studies and T‐cell recognition in PPD‐positive individuals to select proteins and after testing for protective efficacy in animals the most promising proteins have been put together in fusion molecules. Three such fusion proteins are currently in clinical trials, the two most advanced have already passed phase I trials and are entering phase II.